Aelis Farma notifies availability of press release on AEF0217 Phase 2b Down syndrome study update

• Aelis Farma posted a new release on AEF0217 in Down syndrome, citing an IDMC recommendation to continue its Phase 2b trial unchanged.
• Blind safety data to June 4, 2026 covered 42 randomized participants; no serious or severe adverse events were reported.
• Recruitment reached 65 randomized participants, about 37% of the 188 target; enrollment is still expected to finish in 2026.
• Results remain guided for end-2027; the next IDMC review is planned once 40 participants complete 12 weeks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aelis Farma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260715592557) on July 16, 2026, and is solely responsible for the information contained therein.